Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
about
Interventions for mycosis fungoidesTherapeutic options in peripheral T cell lymphomaThe aggressive peripheral T-cell lymphomas: 2013Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.Bendamustine salvage therapy for T cell neoplasms.Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.Gamma-delta t-cell lymphomas.IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Novel therapeutics for aggressive non-Hodgkin's lymphoma.An update on the management of peripheral T-cell lymphoma and emerging treatment optionsReal-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rashStrategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.New drug therapies in peripheral T-cell lymphoma.Brentuximab vedotin for the treatment of CD30+ lymphomas.Targeted molecular therapy in peripheral T-cell lymphomas.Update: peripheral T-cell lymphomas.The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.Novel treatment avenues for peripheral T-cell lymphomas.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.From empiric to mechanism-based therapy for peripheral T cell lymphoma.Emerging drugs for T-cell lymphoma.MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.The aggressive peripheral T-cell lymphomas: 2017.The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.Clinical trials of adult T-cell leukaemia/lymphoma treatment.Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas.Trial Watch: Lenalidomide-based immunochemotherapy.Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.The aggressive peripheral T-cell lymphomas: 2015.Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified
P2860
Q24200749-88396339-52A1-45DA-BB3B-2EF7F89B3C06Q26748857-565A273D-493B-472A-A2FA-C3AC106266C0Q27003257-26BA2306-0BF9-48B0-A9E2-1A266DA8E9B0Q33403802-78138B07-DCC3-4B44-868C-9C7278E540F6Q33405882-75DDADED-1F20-48C9-ABF8-476C9335A1EBQ33407099-07A0E03C-557E-4489-BCE5-14637808BD6FQ33412763-44A42A0F-1267-491D-AE87-9E16D6C968B7Q33417290-573C0728-93A0-4549-B890-00CC2E57F88DQ33702340-CDB68BEE-DF0D-4851-AF42-16F13D61D7A2Q34173071-23AA8DD9-813D-440C-9509-14A7E7EA47B5Q34253548-1E61028A-92CA-461E-AF4C-BD4ECFE9CC5EQ35111768-F9C45176-7732-4486-8B1C-20173BAB768BQ35683871-F704C0BD-F5A6-4214-8A5C-C386B4E530C8Q36052316-76C3A5B7-DC78-4561-8F5B-02573698A4A4Q37391571-A9C8BB89-E509-4659-BC13-46B5E211C642Q37809805-32AA1D2C-8F20-4425-BDE4-930B3867BB90Q37832694-31780AC4-40DC-4366-AE77-C5F4CE24BFB5Q37854715-9AD65F05-4014-4801-A15A-1DBF2B6A5419Q37861212-EFF7BFA0-6490-40DF-B8B0-08B3A95FC13BQ37937044-70E3D2BF-2FA3-4915-B5AE-07F428D8DBF2Q37939715-75EFA0BF-3DBB-4D7D-A752-B06D106FC945Q38003075-E78CB5EE-D5B2-4D12-9DCF-940A19A9F2D8Q38045460-9F968CDC-1F44-46C4-A5BA-05582C7509A2Q38077277-92FE8FE1-7A87-4ACA-9A0D-D8E8AE92C4D8Q38113568-C2F8EAB6-7C54-4579-A881-DF168849A5C8Q38186617-79FF535A-A0A2-4750-BEA1-4F42E3FD755BQ38196943-A3423C1E-BB18-4DB1-A0F2-F8E8E7FE7488Q38260926-8731BDE0-9F37-41C5-8AF9-188C9EB6FFD8Q38940707-FD99E3FE-1B2D-4304-A1B8-49B4976FE427Q40197352-F326BA61-CD7E-41DE-A23D-7FE5298F32F6Q41573605-9DDEF58A-6C60-44C2-9677-7C66328F6333Q41723608-14EEAFFA-8ABF-404E-829D-C4812B4F3774Q42217453-CB53673F-95CA-4B42-A7FF-4DB7FC79488FQ42737828-88875CD7-B335-49EB-88DF-70B45664AEF4Q44647514-18382A64-9137-44FD-80F0-CA462DA7CCCAQ45124918-406B1C62-F3DC-4191-9837-E199602A6BC8Q49046233-D9775F53-644B-428D-8F11-E6AB72827805Q52962544-C5E1028D-5385-4CFB-BF86-100AB7495374Q54959839-477A646A-73B2-46C3-8B17-DD702113794CQ58482092-849F3275-25FE-4665-AB8C-E18719E54815
P2860
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@ast
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@en
type
label
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@ast
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@en
prefLabel
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@ast
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@en
P2093
P356
P1433
P1476
Interim report of a phase 2 cl ...... r T-cell non-Hodgkin lymphoma.
@en
P2093
Andrew Belch
Angeli Prasad
Darrell White
Daygen Finch
Doug Stewart
Greg Dueck
James Johnston
Richard van der Jagt
Tony Reiman
P304
P356
10.1002/CNCR.25377
P407
P577
2010-10-01T00:00:00Z